Expanding its global headquarters in Switzerland, Ferring Pharmaceuticals is investing 30 million Swiss francs (roughly $32 million) in a new biotech center.
In addition to manufacturing biologics (including Rekovelle, the latest of the company’s many fertility treatments), the new facility will have discovery and development capabilities for monoclonal antibodies.
Ferring, a specialty pharma with a long history of making drugs for women and their babies, already operate a number production facilities around the globe, with production facilities from Argentina to Denmark to India.
“Ferring is committed to investing in innovative technology platforms to create new solutions for patients in our core areas of reproductive medicine and women’s health, gastroenterology and urology,” said COO and executive board president Michel Pettigrew. “This significant investment in state-of-the art manufacturing and development technologies fits our strategy to address unmet patient needs in these areas.”
The best place to read Endpoints News? In your inbox.
Comprehensive daily news report for those who discover, develop, and market drugs. Join 35,200+ biopharma pros who read Endpoints News by email every day.Free Subscription